Friday, October 13, 2017 11:38:10 AM
OCTOBER 13, 2017
Fatigue Market Pipeline Review, H1 2017, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics. Fatigue therapeutics industry report provides comprehensive information on the therapeutics under development for Fatigue, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fatigue Market and features dormant and discontinued projects.
Leading Key players in Fatigue Market– Pipeline Review, H1 2017 areAoxing Pharmaceutical Company Inc, BioLite Inc, Biovista Inc, Chronos Therapeutics Ltd, Grifols SA, Hemispherx Biopharma Inc, K-Pax Pharmaceuticals Inc, Merz Pharma GmbH & Co KgaA, MultiCell Technologies Inc and Others.
http://www.satprnews.com/2017/10/13/global-fatigue-therapeutics-report-h1-2017-pipeline-review-of-the-top-drugs-companies-molecules-research-and-markets/
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM